政府更多干预处方药定价的好处

IF 1.7 Q3 HEALTH CARE SCIENCES & SERVICES Health Policy Open Pub Date : 2022-12-01 DOI:10.1016/j.hpopen.2022.100071
Ryan S. Houser
{"title":"政府更多干预处方药定价的好处","authors":"Ryan S. Houser","doi":"10.1016/j.hpopen.2022.100071","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":34527,"journal":{"name":"Health Policy Open","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297769/pdf/","citationCount":"0","resultStr":"{\"title\":\"The benefits of more government interference in prescription drug pricing\",\"authors\":\"Ryan S. Houser\",\"doi\":\"10.1016/j.hpopen.2022.100071\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":34527,\"journal\":{\"name\":\"Health Policy Open\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297769/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Health Policy Open\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2590229622000065\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health Policy Open","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590229622000065","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

摘要

•处方药价格改革获得了两党的支持。•25%的美国人难以负担必要的处方。•价格上限不会阻碍创新,而是常识性的解决方案。•价格上限要求以财政上负责任和道德的方式进行创新。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
The benefits of more government interference in prescription drug pricing
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Health Policy Open
Health Policy Open Medicine-Health Policy
CiteScore
3.80
自引率
0.00%
发文量
21
审稿时长
40 weeks
期刊最新文献
Closing the equity gap: A call for policy and programmatic reforms to ensure inclusive and effective HIV prevention, treatment and care for persons with disabilities in Eastern and Southern Africa Patient’s willingness to pay for improved community health insurance in Tanzania Improving antibiotic prescribing – Recommendations for funding and pricing policies to enhance use of point-of-care tests From theory to practice: Harmonizing taxonomies of trustworthy AI How firearm legislation impacts firearm mortality internationally: A scoping review
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1